Zoetis Inc. (NYSE: ZTS) is named one of the 12 Most Profitable Dividend Stocks to Buy in 2026. Piper Sandler downgrades ZTS to Neutral from Overweight, citing near-term uncertainty despite long-term appeal. The company is in an innovation lull, with questions about consumer spending supporting price points tied to future launches.

During an Innovation Webcast, Zoetis highlights its pipeline with 12 candidates showing blockbuster potential, including programs for chronic kidney disease, oncology, and cardiology. The company emphasizes a balanced strategy focusing on geographic expansion, lifecycle extensions, and new products to strengthen existing franchises and drive industry progress.

Zoetis Inc. (NYSE: ZTS) is a global animal health company specializing in medicines, vaccines, diagnostics, biodevices, genetic tests, and precision health tools for animals. While ZTS has investment potential, certain AI stocks may offer greater upside potential and lower downside risk.

For more financial insights, check out the Dividend Contenders List: Top 20 Stocks and 15 Best High Yield Stocks To Buy. No disclosure provided in the article.

Read more at Yahoo Finance.: Piper Sandler Flags Near-Term Uncertainty for Zoetis (ZTS) Despite Long-Term Appeal